Amgen Inc. et al. v. Sanofi et al.
598 U.S. 5942023 USPQ2d 602SCOTUS
AI-generated holding
The full scope of a genus claim must be enabled—the more one claims, the more one must enable; claims to a genus of monoclonal antibodies defined functionally by their binding ability, rather than by structure, were invalid for lack of enablement.
- Written by
- A language model, from how the MPEP uses this case rather than from the opinion.
- Confidence
- high — self-reported, not calibrated against a measured error rate
- Human review
- Not reviewed by a person
Read the opinion before relying on this in a filing. How these are made · Report an error
Cited by the manual
5 sections§ 2164.01→§ 2164.01(a)→§ 2164.02→§ 2164.08→§ 2164.06→
The Enablement Requirement
“full scope of a genus claim must be enabled; the more one claims, the more one must enable”
The Enablement Requirement
“full scope of a genus claim must be enabled; the more one claims, the more one must enable”
The Enablement Requirement
“full scope of a genus claim must be enabled; the more one claims, the more one must enable”
The Enablement Requirement
“full scope of a genus claim must be enabled; the more one claims, the more one must enable”
The Enablement Requirement
“full scope of a genus claim must be enabled; the more one claims, the more one must enable”